Adiponectin is an adipokine exclusively expressed in adipose tissues with potent anti-diabetic, anti-atherogenic and anti-inflammatory functions.
In humans, decreased serum adiponectin levels are associated with increased body mass index (BMI), decreased insulin sensitivity, less favourable plasma lipid profiles, increased inflammation and increased risk for the development of type 2 diabetes, hypertension and coronary heart diseases.
In humans, high circulating FGF21 levels are found in obesity and multiple cardiometabolic disorders, including metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease and coronary artery disease. Serum FGF21 is a potential biomarker for the early detection and risk prediction of these diseases.
TYPICAL STANDARD CURVE
The following standard curve is provided for demonstration only. A standard curve should be generated for each assay.
Human adiponectin standard curve (4-parameter)
The lowest level of human adiponectin that can be detected by this assay is 0.78 ng/ml.
The antibody pair used in this assay is specific to human adiponectin and does not cross-react with mouse and rat adiponectin, and other cytokine or hormone molecules including human resistin, TNFα, ANGPTL4, insulin, leptin and IL6.
The assay variations of this ELISA kits were studied on four human serum samples with varying concentrations of endogenous adiponectin. The mean within variation was calculated from results of five duplicate determinations in each assay of the indicated samples. The mean between variations of each sample was calculated from results of four separate assays with duplicate samples in each assay.